Immune cell duo takes on tough tumors in early trial
NCT ID NCT07475182
First seen Mar 28, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This early-phase study tests a combination of two immune cell therapies—targeted dendritic cells and CAR-T cells—in 10 adults with advanced solid cancers like stomach, colon, or pancreatic cancer. The goal is to see if the treatment is safe and can shrink tumors by helping the immune system attack cancer more effectively. Participants must have tumors that test positive for a specific protein called Claudin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hainan Cancer Hospital
RECRUITINGHaikou, Hainan, 570311, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.